1
|
Schirmer D, Grünewald TGP, Klar R, Schmidt O, Wohlleber D, Rubío RA, Uckert W, Thiel U, Bohne F, Busch DH, Krackhardt AM, Burdach S, Richter GHS. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity. Oncoimmunology 2016; 5:e1175795. [PMID: 27471654 DOI: 10.1080/2162402x.2016.1175795] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Revised: 03/31/2016] [Accepted: 04/01/2016] [Indexed: 12/20/2022] Open
Abstract
Pediatric cancers, including Ewing sarcoma (ES), are only weakly immunogenic and the tumor-patients' immune system often is devoid of effector T cells for tumor elimination. Based on expression profiling technology, targetable tumor-associated antigens (TAA) are identified and exploited for engineered T-cell therapy. Here, the specific recognition and lytic potential of transgenic allo-restricted CD8(+) T cells, directed against the ES-associated antigen 6-transmembrane epithelial antigen of the prostate 1 (STEAP1), was examined. Following repetitive STEAP1(130) peptide-driven stimulations with HLA-A*02:01(+) dendritic cells (DC), allo-restricted HLA-A*02:01(-) CD8(+) T cells were sorted with HLA-A*02:01/peptide multimers and expanded by limiting dilution. After functional analysis of suitable T cell clones via ELISpot, flow cytometry and xCELLigence assay, T cell receptors' (TCR) α- and β-chains were identified, cloned into retroviral vectors, codon optimized, transfected into HLA-A*02:01(-) primary T cell populations and tested again for specificity and lytic capacity in vitro and in a Rag2(-/-)γc(-/-) mouse model. Initially generated transgenic T cells specifically recognized STEAP1(130)-pulsed or transfected cells in the context of HLA-A*02:01 with minimal cross-reactivity as determined by specific interferon-γ (IFNγ) release, lysed cells and inhibited growth of HLA-A*02:01(+) ES lines more effectively than HLA-A*02:01(-) ES lines. In vivo tumor growth was inhibited more effectively with transgenic STEAP1(130)-specific T cells than with unspecific T cells. Our results identify TCRs capable of recognizing and inhibiting growth of STEAP1-expressing HLA-A*02:01(+) ES cells in vitro and in vivo in a highly restricted manner. As STEAP1 is overexpressed in a wide variety of cancers, we anticipate these STEAP1-specific TCRs to be potentially useful for immunotherapy of other STEAP1-expressing tumors.
Collapse
Affiliation(s)
- David Schirmer
- Children's Cancer Research Center and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany and Comprehensive Cancer Center Munich (CCCM) , Munich, Germany
| | - Thomas G P Grünewald
- Laboratory for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich , Munich, Germany
| | - Richard Klar
- Medical Department III, Hematology and Oncology , Munich, Germany
| | - Oxana Schmidt
- Children's Cancer Research Center and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany and Comprehensive Cancer Center Munich (CCCM) , Munich, Germany
| | - Dirk Wohlleber
- Institute of Molecular Immunology/Experimental Oncology, Klinikum rechts der Isar, Technische Universität München , Munich, Germany
| | - Rebeca Alba Rubío
- Laboratory for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich , Munich, Germany
| | - Wolfgang Uckert
- Max Delbrück Center for Molecular Medicine , Berlin, Germany
| | - Uwe Thiel
- Children's Cancer Research Center and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany and Comprehensive Cancer Center Munich (CCCM) , Munich, Germany
| | - Felix Bohne
- Institute of Virology, Technische Universität München, Helmholtz Zentrum München , Munich, Germany
| | - Dirk H Busch
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München , Munich, Germany
| | | | - Stefan Burdach
- Children's Cancer Research Center and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany and Comprehensive Cancer Center Munich (CCCM) , Munich, Germany
| | - Günther H S Richter
- Children's Cancer Research Center and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany and Comprehensive Cancer Center Munich (CCCM) , Munich, Germany
| |
Collapse
|